Citi upgraded Zip to a Buy last Friday, citing strong US growth, new product potential and further earnings momentum.

Healthcare stocks are facing steep losses as several names have either manufacturing facilities in the tariffed countries and ...

A recap of the most heavily shorted stocks on the ASX and those experiencing significant changes to short interest over the ...

See Upcoming Dividends for all ASX companies.

See Upcoming Dividends for all ASX companies.

All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits) ...

All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits) ...

Welcome back to the Insider Trades Series – A weekly summary of on-market ASX director transactions valued at more than ...

Apple (-0.6%) 1Q25 EPS beat, with gross margins 40 bps above estimates, iPhone revenue missed by ~2%, Mac and iPad ...

Full-year EBITDA guidance cut to $11-14 million vs. prior guidance of $11-16 million (7.4% downgrade at the midpoint) Full-year revenue guidance cut to $260-270 million vs. prior guidance of $280-290 ...

ResMed (ASX: RMD) posted a solid December quarter, with most figures slightly exceeding market expectations, driven by strong device growth. US device growth: “Global device sales were driven by ...

For a detailed explanation of Carl's technical analysis methodology, be sure to check out this ChartWatch Primer. Carl has over 30-year's investing experience, helping investors navigate several bull ...